Genomic scarring score predicts the response to PARP inhibitors in non-small cell lung cancer

Abstract PARP inhibitors (PARPi) have shown efficacy in tumours harbouring mutations in homologous recombination repair (HRR) genes. Somatic HRR mutations have been described in patients with Non-Small Cell Lung Cancer (NSCLC), but PARP inhibitors (PARPi) are not yet a therapeutic option. Here we as...

Полное описание

Библиографические подробности

Главные авторы:	Katerina Tsilingiri, Anna Chalari, Georgia Christopoulou, Alexandra Voutsina, Pantelis Constantoulakis, Κonstantinos Potaris, Ioannis Vamvakaris, Dora Hatzidaki, Georgina Zachou, Giannis Vatsellas, Vassilis Georgoulias, Athanasios Kotsakis, Apostolos Klinakis
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Nature Portfolio 2024-12-01
Серии:	npj Precision Oncology
Online-ссылка:	https://doi.org/10.1038/s41698-024-00777-6
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!